Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas

BACKGROUND: Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent and durable effects in B-cell malignancies. However, antigen loss or downregulation is a frequent cause of resistance. Here, we report development of a novel CAR T-cell therapy product to target CD79b, a pan B-cell ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Fuliang, Cao, Jingjing, Liu, Jingwei, Yang, Haopeng, Davis, Timothy J, Kuang, Shao-qing, Cheng, Xiaoyun, Zhang, Zheng, Karri, Swathi, Vien, Long T, Bover, Laura, Sun, Ryan, Vega, Francisco, Green, Michael, Davis, Richard Eric, Neelapu, Sattva S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680003/
https://www.ncbi.nlm.nih.gov/pubmed/38007239
http://dx.doi.org/10.1136/jitc-2023-007515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680003/
https://www.ncbi.nlm.nih.gov/pubmed/38007239
http://dx.doi.org/10.1136/jitc-2023-007515

Ejemplares similares